Cellectar Biosciences Statistics
Share Statistics
Cellectar Biosciences has 41.27M shares outstanding. The number of shares has increased by 191.73% in one year.
| Shares Outstanding | 41.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 40.04M |
| Failed to Deliver (FTD) Shares | 1.58K |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 1.84M, so 4.45% of the outstanding shares have been sold short.
| Short Interest | 1.84M |
| Short % of Shares Out | 4.45% |
| Short % of Float | 4.59% |
| Short Ratio (days to cover) | 8.34 |
Valuation Ratios
The PE ratio is -0.89 and the forward PE ratio is -0.76.
| PE Ratio | -0.89 |
| Forward PE | -0.76 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | -24.97 |
| P/FCF Ratio | -1.02 |
| PEG Ratio | n/a |
Enterprise Valuation
Cellectar Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.81, with a Debt / Equity ratio of -0.04.
| Current Ratio | 0.81 |
| Quick Ratio | 0.81 |
| Debt / Equity | -0.04 |
| Total Debt / Capitalization | -4.55 |
| Cash Flow / Debt | -548.96 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 28.01% and return on capital (ROIC) is 4843.84%.
| Return on Equity (ROE) | 28.01% |
| Return on Assets (ROA) | -3.15% |
| Return on Capital (ROIC) | 4843.84% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.90M |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -60.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -90.57% in the last 52 weeks. The beta is 1.01, so Cellectar Biosciences 's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | -90.57% |
| 50-Day Moving Average | 1.78 |
| 200-Day Moving Average | 2.57 |
| Relative Strength Index (RSI) | 5.9 |
| Average Volume (20 Days) | 1.15M |
Income Statement
In the last 12 months, Cellectar Biosciences had revenue of $0 and earned -$37.98M in profits. Earnings per share was $-3.11.
| Revenue | 0 |
| Gross Profit | -192.38K |
| Operating Income | -38.96M |
| Net Income | -37.98M |
| EBITDA | -38.77M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.11 |
Balance Sheet
The company has $9.56M in cash and $552.98K in debt, giving a net cash position of $9.01M.
| Cash & Cash Equivalents | 9.56M |
| Total Debt | 552.98K |
| Net Cash | 9.01M |
| Retained Earnings | -217.48M |
| Total Assets | 37.29M |
| Working Capital | 15.58M |
Cash Flow
In the last 12 months, operating cash flow was -$32.38M and capital expenditures -$864.04K, giving a free cash flow of -$33.24M.
| Operating Cash Flow | -32.38M |
| Capital Expenditures | -864.04K |
| Free Cash Flow | -33.24M |
| FCF Per Share | -2.72 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CLRB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1244% |
| FCF Yield | -319.5% |
Analyst Forecast
The average price target for CLRB is $28, which is 11100% higher than the current price. The consensus rating is "Hold".
| Price Target | $28 |
| Price Target Difference | 11100% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 22, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 22, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -12.96 |
| Piotroski F-Score | 2 |